Blue Owl Capital Holdings »

Evommune shares owned by Blue Owl Capital Holdings

Quarter-by-quarter ownership of Evommune (EVMN) shares owned by Blue Owl Capital Holdings from 13F filings

Historical chart of Blue Owl Capital Holdings investment in Evommune

Tip: Access up to 7 years of quarterly data

All positions including Evommune held by Blue Owl Capital Holdings consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Evommune by Blue Owl Capital Holdings

Quarter filed Position value Share count Share price at filing
2026-03-31 $2.3M 100k 22.99

More positions owned by Blue Owl Capital Holdings

Aktis Oncology
Larimar Therapeutics (LRMR)
Engene Holdings (ENGN)
Nuveen Churchill Direct Lend Com Shs (NCDL)
Cullinan Oncology (CGEM)
Owl Rock Capital Corporation (OBDC)
Maplight Therapeutics (MPLT)
Compass Therapeutics (CMPX)
Context Therapeutics (CNTX)
Holley (HLLY)
Eyepoint Com New (EYPT)
Corvus Pharmaceuticals (CRVS)
Conduent Incorporate (CNDT)
Ultragenyx Pharmaceutical (RARE)
Aquestive Therapeutics (AQST)

View all positions for Blue Owl Capital Holdings

Top funds holding Evommune

EQT Fund Management S.a r.l.
RA Capital Management
Pivotal bioVenture Partners Investment Advisor
Andera Partners
Rtw Investments
MPM Oncology Impact Management
Nan Fung Group Holdings
SymBiosis Capital Partners
Eventide Asset Management
Henderson Group
Marshall Wace
Baker Bros. Advisors
Alyeska Investment Group
Defilade Capital Management
BlackRock

View all funds holding Evommune